Novartis Cholesterol Drug Fail Shakes Billion-Dollar Lp(a) Race
Novartis' Lp(a)-lowering drug disappointment puts pressure on Amgen and Eli Lilly to prove the approach can cut heart attacks and strokes.
A high-profile setback for Novartis in the race to develop next-generation cholesterol drugs is casting serious doubt over one of the pharmaceutical industry's most competitive and expensive scientific bets, raising urgent questions about whether reducing levels of lipoprotein(a) — a genetic risk factor for cardiovascular disease — will actually translate into fewer heart attacks and strokes for patients.
Novartis' failure is a significant blow because the company was among the frontrunners in what analysts have pegged as a multibillion-dollar market opportunity. The drug's stumble does not just hurt Novartis — it rattles the broader thesis underpinning years of research and investment by rival firms who are still deep in the same arena.
Read more Jindal Steel Builds World's Longest Steel Slag Road in India →
Amgen and Eli Lilly now face dramatically heightened scrutiny as they continue advancing their own Lp(a)-targeting therapies through clinical development. Where Novartis once provided potential validation for the entire approach, its disappointment forces investors and regulators alike to ask harder questions about whether lowering Lp(a) is truly sufficient to deliver the cardiovascular outcomes patients and doctors need.
The setback underscores a persistent challenge in cardiology drug development: biomarker improvement — in this case, measurably lower Lp(a) levels — does not automatically guarantee clinical benefit. That distinction, between changing a number on a lab report and actually preventing life-threatening events, is the critical hurdle that Amgen and Eli Lilly must now clear convincingly with their own trial results.
The stakes for the remaining players could not be higher. Success would unlock a vast, largely untreated patient population with genetically elevated Lp(a); failure could shut down an entire therapeutic category. Continue reading at US Top News and Analysis.
